Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions

Neuropathy;Peripheral

Interventions

DEVICE

Abbott® DRG / Abbott®/Medtronic® SCS

Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.

OTHER

Control Group

Participants will not receive any intervention

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Foundation for Anesthesia Education and Research

OTHER

lead

M.D. Anderson Cancer Center

OTHER